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Paclitaxel coating of the luminal surface of
hemodialysis grafts with effective suppression of
neointimal hyperplasia
Insu Baek, MS,a Cheng Zhe Bai, PhD,a Jinsun Hwang, MS,b Hye Yeong Nam, PhD,a
Jong-Sang Park, PhD,a and Dae Joong Kim, MD,b Seoul, Republic of Korea
Objectives: Paclitaxel coating of hemodialysis grafts is effective in suppressing neointimal hyperplasia in the graft and
vascular anastomosis sites. However, paclitaxel can have unwanted effects on the surrounding tissues. To reduce such
problems, we developed a method to coat the drug only on the luminal surface of the graft, with little loading on the outer
surface.
Methods: A peristaltic pump and a double-solvent (water and acetone) system were used to achieve an inner coating of
paclitaxel. At the ratio of 90% acetone, paclitaxel was homogeneously coated only on the luminal surface of the graft
without changing the physical properties. To determine its effect, grafts were implanted between the common carotid
artery and the external jugular vein in pigs using uncoated control grafts (n 6) and low-dose (n 6, 0.22g/mm2) and
high-dose (n  6, 0.69 g/mm2) paclitaxel inner-coated grafts. Cross-sections of graft–venous anastomoses were
analyzed histomorphometrically 6 weeks after placement to measure the patency rate, percentage of luminal stenosis, and
neointimal area.
Results: No signs of infection or bacterial contamination were observed in the paclitaxel inner-coated groups. Only one of
the six control grafts was patent, but all of the paclitaxel-coated grafts were patent, with little neointima. The mean 
standard error values of percentage luminal stenosis were 75.7%  12.7% (control), 17.5%  3.1% (low dose), and
19.7%  3.0% (high dose). The values for the neointimal area (in mm2) were 8.77  1.66 (control), 3.53  0.73 (lose
dose), and 4.24  0.99 (high dose). Compared with the control group, paclitaxel inner-coated vascular grafts
significantly suppressed neointimal hyperplasia (low dose, P  .001; high dose, P  .002). Myofibroblast proliferation
and migration into the graft interstices confirmed the firm attachment of the implanted graft to the surrounding tissue.
Conclusions: Paclitaxel coating on the inner luminal surface of vascular grafts was effective in suppressing neointimal
hyperplasia, with little inhibition of myofibroblast infiltration within the graft wall. ( J Vasc Surg 2012;55:806-14.)
Clinical Relevance. Paclitaxel-coated vascular grafts effectively inhibited the neointimal hyperplasia of hemodialysis
grafts. However, paclitaxel on the outer surface of expanded polytetrafluoroethylene grafts might prevent myofibroblast
proliferation, which might cause hematomas, seromas, infections, or pseudoaneurysms in the space between the graft and
surrounding tissue and result in incomplete hemodialysis needle insertion. Therefore, paclitaxel inner-coated expanded
polytetrafluoroethylene grafts can reduce the coated amount of this potentially toxic drug to avoid such unwanted effects,
whilst preserving its efficacy in inhibiting stenosis.
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eMillions of patients with end-stage renal disease de-
pend on lifelong hemodialysis for the removal of metabolic
wastes.1 Preparing vascular access for repeated needle
puncture and adequate blood flow is a prerequisite for such
maintenance hemodialysis. Grafts made of expanded poly-
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806etrafluoroethylene (ePTFE) are used frequently. The most
mportant cause of graft dysfunction is thrombosis and
tenosis caused by the aggressive development of venous
eointimal hyperplasia, especially at the graft–venous anas-
omosis site. The proliferation and migration of vascular
moothmuscle cells andmyofibroblasts into the neointimal
ayer can result in a pathologic narrowing of the access.2
here have been many efforts to prevent stenosis through
nhibiting smooth muscle cell proliferation and migration
sing local delivery of potent antiproliferative agents such
s paclitaxel or sirolimus.3-9
We previously reported that paclitaxel coating of
PTFE grafts was effective in suppressing such neointimal
yperplasia and stenosis.10,11 Various methods of coating
ere also developed for controlled drug delivery, such as
he dipping method, double dipping,12 and loading of
aclitaxel nanoparticles onto ePTFE vascular grafts.13 With
ur previous dip-coating methods, paclitaxel was coated
qually on the inner and outer surfaces of the graft. How-
ver, because a high local concentration of paclitaxel is
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Volume 55, Number 3 Baek et al 807toxic, its location on the outside of vascular grafts can
reduce myofibroblast proliferation, resulting in possible
inhibition of adhesion between the graft and the surround-
ing tissue.14 Moreover, because the neointimal hyperplasia
is almost always observed on the inner surfaces of vascular
and graft lumens, drug coating on the inner surface of the
graft with little loading on the outer surface can inhibit
neointimal hyperplasia, thereby avoiding the unwanted ef-
fects of the drug on the tissues surrounding the graft.
In this study, we developed a novel coating method to
load the drug only on the inner surface of the graft. We
evaluated the effect of the paclitaxel inner-coated graft on
inhibiting neointimal hyperplasia in a pig model.
METHODS
Paclitaxel (Genexol) was purchased from Samyang
Genex Inc, South Korea. The ePTFE vascular grafts
(IMPRA, F4006C) were purchased from Bard Peripheral
Vascular Inc, Tempe, Ariz. The PTFE tape (NasaSeal) was
purchased from Hanyang Chemical, South Korea. High-
performance liquid chromatography (HPLC)-grade ace-
tone and acetonitrile were obtained from Fisher Scientific,
Waltham, Mass. Tween 20 was purchased from Hayashi
Pure Chemical Industries Ltd, Osaka, Japan. Phosphate-
buffered saline (PBS) was obtained from Cambrex Corp,
East Rutherford, NJ.
Preparation of paclitaxel-coated ePTFE grafts.
Paclitaxel was loaded onto the luminal surface of the
ePTFE vascular grafts as follows: PTFE tape was wrapped
tightly around the graft, and a silicon tube was connected
to the graft. Paclitaxel was dissolved in a mixture of acetone
and water at a 9:1 (v/v) ratio to a concentration of 5 or 15
mg/mL. The coating solution was passed through the graft
lumen using a peristaltic pump (Masterflex 7518-00; Cole-
Parmer Instrument Company, Vernon Hills, Ill) at 8 rpm
for 2.5 minutes. Nitrogen gas was injected through the
graft lumen for fast drying of the residual coating solution,
which suppressed diffusion of the remaining solution.
The grafts were dried and maintained in a vacuum
overnight. After the PTFE tape wrapping, the graft was
peeled off, and the ePTFE graft was packed and sterilized in
ethylene oxide gas. The corresponding amounts of pacli-
taxel on the grafts at these concentrations were 0.22 and
0.69 g/mm2, respectively.
Morphologic characterization. Surface morphologic
changes of the paclitaxel inner-coated ePTFE graft were
analyzed using a scanning electron microscope (SEM; JSM
840-A, Jeol Ltd, Tokyo, Japan). Six samples taken from the
control and paclitaxel inner-coated graft were evaluated to
randomly scan the surface morphology.
Measurement of amount of the paclitaxel coating.
To determine the amount of paclitaxel coating the graft,
the drug-coated graft was divided with 5-cm cuts. The
grafts were soaked in 8 mL of methanol in polypropylene
tubes and shaken for 30 minutes, until the paclitaxel coat-
ing was completely released into the methanol. The pacli-
taxel concentration of the solution was analyzed by HPLC
(Agilent 1200 Series, Santa Clara, Calif). HPLC analysis ras performed using a water–acetonitrile gradient system
50% acetonitrile for 12 minutes, 90% for 21 minutes, 50%
or 30 minutes) at a flow rate of 0.8 mL/min, a 4.6- 
50-mm C18 reverse-phase column, and an ultraviolet
etector set at 227 nm.Under these conditions, the peak of
aclitaxel was eluted at 9.50 minutes.
The diameter of ePTFE graft was 6 mm, thus the
urface area of the 5-cm graft segment was calculated using
he formula: 6 mm    50 mm. Therefore, the drug
oating amount per unit area was calculated by dividing the
aclitaxel coating amount of the 5-cm graft by the surface
rea of the 5-cm graft.
To verify the gradient loading of paclitaxel from the
nner to the outer wall, the paclitaxel coating solution with
arious acetone ratios (60%, 70%, 80%, 90%, and 100%,
espectively) was perfused through the graft lumen. After
aclitaxel coating, the unseasoned ePTFE graft wrapped
ith PTFE tape was centrifuged at 2000 rpm for 5 minutes
n a vertically connected stirrer. Because acetone is very well
bsorbed on the PTFE tape, as well as on the ePTFE graft,
he residual coating solution in the graft lumen may be
uickly permeated into the PTFE tape by the centrifugal
orce.
The paclitaxel content of PTFE tape was measured as
eflecting the amount of coated drug. If the paclitaxel-
issolved solution is permeated on the luminal surface of
PTFE graft with a shallow depth, a small quantity of the
rug will be detected in the PTFE tape when the coating
olution exudes from the inside wall of the graft by the
entrifugal force of spinning. For the quality control of this
oating method, the means of five experiments were ana-
yzed.
In vitro release test. For in vitro release studies, we
sed PBS (pH, 7.4) containing 0.05% (w/v) Tween 20.
ndividual 5-cm-long grafts were placed in polypropylene
ubes containing 8 mL of release medium and incubated at
7°C and 20 rpm in a hybridization incubator (Combi-H;
INEPCR, Seoul, South Korea). At the designated times,
eleasing medium was removed completely from the tubes
nd stored for analysis for a total duration of about 28 days.
he medium was replaced with 8 mL of fresh release
edium. The amount of paclitaxel released into the me-
ium was measured using HPLC.
Experimental animals and operative technique.
ighteen female Landrace pigs (weight, 50  7 kg) re-
eived one of three types of grafts between the common
arotid artery and the external jugular vein: grafts without
aclitaxel coating (control, n  6), and paclitaxel-coated
rafts at a dose density of 0.22 g/mm2 (low-dose, n 6)
r 0.69 g/mm2 (high-dose, n  6). The animals were
aintained in standard animal care facilities at Samsung
iomedical Research Institute (SBRI). This study was re-
iewed and approved by the Institutional Animal Care and
se Committee of SBRI.Operating procedures conformed
o the Guidelines for the Care and Use of Laboratory Ani-
als (National Institutes of Health publication No. 85-23,
evised 1996).
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March 2012808 Baek et alPigs were anesthetized with intramuscular ketamine
HCl (20 mg/kg) and xylazine HCl (2 mg/kg) and were
intubated and ventilated with a mixture of oxygen and air
(1:2) containing enflurane (2%) for maintenance anesthe-
sia. Vecuronium bromide (0.1 mg/kg) was administered
continuously through an ear vein.
As in previous studies, we adopted the animal experi-
ment model proposed by Rotmans et al.15 After standard
surgical cleansing, a longitudinal incision was made in the
lateral side of the neck along the sternocleidomastoid mus-
cle. The common carotid artery and the external jugular
vein were exposed, and heparin (100 IU/kg) was given
intravenously before vessel manipulation. The common
carotid artery was clamped using vessel loops and an 8-mm
arteriotomy was made. An end-to-side anastomosis was
made at approximately 45° using a 6-0 polypropylene
suture. Venous anastomoses were created in a similar man-
ner. From surgery day to the day of euthanasia, all pigs were
administered aspirin (100 mg/d) and clopidogrel (75
mg/d; Plavix, Sanofi Aventis, France).
At 6 weeks after the operation, anesthesia was induced,
the implanted grafts were excised along with adjacent ves-
sels, and the animals were euthanized. The implanted
grafts were immediately placed in heparin-containing PBS
(10,000 IU/L) to remove the remaining blood from the
vessels. The sample was immersion-fixed in 10% neutral-
buffered formalin for at least 24 hours and embedded in
paraffin.
Tissue preparation and morphometry. Sections (5
m) of veins 1-cm proximal and distal to anastomosis were
prepared perpendicular to the blood flow. Serial sections
were taken to obtain cross-sections around the center of the
graft–venous anastomosis, and three sections were analyzed
to determine the percentage of luminal stenosis (Fig 1).
All sections were stained with hematoxylin and eosin
Fig 1. Diagrams show the graft–venous anastomosis. A
expanded polytetrafluoroethylene (ePTFE) graft and vein
center of the graft–venous anastomosis, and three of th
luminal stenosis. One section was obtained at the cente
proximal side and 2 mm to the distal side from the cente
cross-section is shown.(H&E) to roughly confirm the presence of inflammation tround the implanted ePTFE graft and were further sta-
ioned with Masson’s trichrome. The areas of intima and
edia were manually traced on captured images obtained
ith an Aperio ImageScope (Ronkonkoma, NY). To com-
are stenosis among the control and paclitaxel inner-coated
roups, the percentage of luminal stenosis was calculated
rom the area of neointima divided by the total luminal area
nside grafts and vascular tissues. We measured the percent-
ges of luminal stenoses in three sections from each graft–
enous anastomosis site, and the mean values for these
hree sections were analyzed to compare among the
roups. Neointimal areas in the venous lumens of each
roup were measured for quantitative analysis in the same
ay.
Immunohistochemical staining. Sections (5 m) of
araffin-embedded tissues were immunostained with anti-
odies to -smooth muscle actin (SMA; Abcam Plc, Cam-
ridge, UK), vimentin (AbD Serotec, Oxford, UK), and
esmin (GeneTex, Irvine, Calif) using Vectastain ABC kits
Vector Laboratories, Burlingame, Calif) according to the
anufacturer’s instructions. Briefly, sections were deparaf-
nized and hydrated through a xylene and graded alcohol
eries. After antigen retrieval in antigen unmasking solution
Vector Laboratories) for 15 minutes, the slides were incu-
ated in 0.3% H2O2 for 30 minutes, in normal blocking
erum for 20 minutes, in primary antibody overnight at
°C, in biotinylated secondary antibody for 30 minutes, in
ectastain ABC reagent for 30 minutes, and in peroxidase
ubstrate solution. The sections were then counterstained
ith hematoxylin and dehydrated through a graded alcohol
eries.
To analyze the number and cellular phenotypes for
djacent tissue outside the graft wall, semiquantitative scor-
ng of all sections was performed on a scale from 0 to 4,
hich corresponded to the percentage of positive cells for
intimal hyperplasia can easily build up at the junction of
l sections were taken to obtain cross-sections around the
ections were analyzed to find the mean percentage of
he anastomosis; the others were obtained 2 mm to the
he anastomosis. B, Intragraft and venous region of the, Neo
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Volume 55, Number 3 Baek et al 809positive; 1, 11%-25% positive; 2, 26%-50% positive; 3,
51%-75% positive; and 4, 76%-100% positive).16
Statistical analysis. We used repeated measure analy-
sis of variance to compare the in vitro drug release profiles
of the three kinds of paclitaxel-coated grafts. Unpaired
Student t-tests were used to compare the percentages of
luminal stenosis and neointimal between the two groups;
P .05 was considered statistically significant. Continuous
data are presented as mean values the standard error. We
used SPSS 18.0 software (SPSS Inc, Chicago, Ill) for all
statistical analyses.
RESULTS
Characterization of inner coating method. The pac-
litaxel coating solution was able to perfuse inside the graft
without diffusion through the wall at an appropriate sol-
vent volume ratio of water and acetone, probably due to the
hydrophobicity of ePTFE. Acetone is essential to dissolve
paclitaxel, because the drug is not soluble in water. As the
ratio of water to acetone decreased, the solution dissolved
the drug better, but diffusion and leakage from inside the
grafts increased. However, the permeation of coating solu-
tion into the outer surface of grafts decreased rapidly when
we increased the water/acetone ratio. When we used 60%
acetone solution for inner coating, heterogeneous aggre-
gation was produced on the inner surface of the graft. With
90% acetone solution, there was little outer paclitaxel, with
Fig 2. Gradient loading of paclitaxel from the inner to
(v/v) of coating solutions: 7:3, 8:2, 9:1, and only a
polytetrafluoroethylene (ePTFE) graft wrapped with PTF
considered the index for in-depth penetration of the coa
outer ratio of paclitaxel was calculated as the paclitaxel
paclitaxel (ie, on both the ePTFE graft and the PTFE
represent the standard error.small variation. (As shown in Fig 2, a very small amount of the 70%
cetone solution was permeated to the graft wall, and
aclitaxel was not detected on the PTFE tape when dried by
itrogen gas. Spinning the ePTFE graft with PTFE tape
orced unseasoned coating solution to move outward, and
very small amount of paclitaxel was detected on the PTFE
ape. In the 90% acetone ratio, more paclitaxel was detected
n the PTFE tape when dried by centrifugation, which
eant more paclitaxel was loaded on the luminal surface of
he graft but did not seep into the outer wall. As a result, the
aclitaxel coating solutions with a higher acetone ratio
ended to permeate more drug outwards, showing that
ore hydrophobic coating solution penetrated deeper into
he graft wall.
The SEM images of the paclitaxel inner-coated ePTFE
raft showed a homogeneous surface, similar to the control
raft (Fig 3). Because the constriction of the inner lining of
he ePTFE graft could make the graft wall stiff, these results
xplained that two types of grafts had similar elasticity.
In vitro release profiles of paclitaxel. Because in
itro drug release was influenced by the concentration of
urfactant, direct comparison with the in vivo condition was
ot available. Instead, we compared drug-release profiles
ccording to the types of paclitaxel coating under the same
elease condition. The in vitro drug-release profiles for 28
ays were measured to compare release patterns according
o the coated amount of paclitaxel and the coating method
uter wall, according to the various acetone/water ratios
e. After centrifugation of the unseasoned expanded
e, the amount of paclitaxel loading in the PTFE tape was
solution from the luminal surface to the graft wall. The
unt on the PTFE tape divided by the total amount of
. Data are the means of five experiments, and the barsthe o
ceton
E tap
ting
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March 2012810 Baek et almg/mL paclitaxel in acetone, which had a similar amount
of drug as the high-dose inner-coated group, showed dif-
ferent drug release kinetics. The paclitaxel inner-coated
grafts showed faster cumulative drug release than the grafts
coated by the dipping method. Even in the high-dose
grafts, more than 45% of the loaded paclitaxel remained
after 28 days.
Animal experiments and histomorphometry. At 6
weeks after implantation, the surgical sites were well healed
in all animals, and no inflammation was evident on H&E
staining (shown in the Appendix, online only). Infection
Fig 3. Scanning electron microscope images of expande
after drug coating. After paclitaxel coating, no significan
ePTFE graft.
Fig 4. Cumulative in vitro release profiles from the pac
inner-coating method of low dose and high dose (P  .
means of five experiments, and the bars represent standawas defined as the presence of pus and cloudy exudate ground the surgical site, and no signs of infection or bacte-
ial contamination were observed at the implantation sites
f the control or the paclitaxel inner-coated groups at 6
eeks. Cross-sections from graft–venous anastomoses in
he control and paclitaxel inner-coated groups (Fig 5)
howed that the upper graft region was entirely occluded,
nd the lower venous region was patent (Fig 5, B). In this
ase, the blood flow could not be measured using Doppler
maging; therefore, we considered that the graft was oc-
luded when the percentage of luminal stenosis was	50%.
epending on this assumption, only one of the six control
ytetrafluoroethylene (ePTFE) grafts (A) before and (B)
ference was observed in the surface morphology of the
l-coated grafts made by the dipping method and by the
y repeated measures analysis of variance). Data are the
or.d pol
t diflitaxe
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Volume 55, Number 3 Baek et al 811patent, with little neointima. No occlusion due to throm-
bosis was detected in the 12 pigs that received the paclitaxel
inner-coated graft. Therefore, the paclitaxel coating is not
thought to affect the occurrence of thrombosis.
To compare neointimal hyperplasia quantitatively, we
measured the percentages of luminal stenosis and neointi-
mal areas in the graft–venous anastomosis sites (Fig 6). The
percentages of luminal stenosis were 75.7% 12.7% in the
control group, 17.5% 3.1% in the low-dose, and 19.7%
3.0% in the high-dose paclitaxel inner-coated group. Simi-
larly, the neointimal areas were 8.77  1.66 mm2 in the
control group, 3.53  0.73mm2 in the low-dose, and
4.24  0.99 mm2 in the high-dose paclitaxel inner-coated
group. The percentage of luminal stenosis was significantly
lower in all paclitaxel-coated groups, compared with con-
trols, and a similar trend was observed when comparing the
neointimal area. No dose effect was apparent (P 	 .05).
The deviation of neointimal area was greater than that of
the percentage luminal stenosis, which was due to the
Fig 5. Representative cross-sections of the graft–venous
D) low-dose and (E and F) high-dose paclitaxel inner-
recognized as the pale blue stained area in the intragraft
Fig 6. Comparison of the (A) percentage of luminal sten
and the paclitaxel inner-coated groups (low dose, n  6;
between the control and paclitaxel inner-coated groups
t-test).variation of vessel thickness between the experimental ani- tals. Nevertheless, the difference in neointimal areas be-
ween the control group and paclitaxel inner-coated groups
as statistically significant (Fig 6, B).
Immunohistochemistry. Fig 7 shows representative
ections from the control and low-dose groups at 6 weeks
fter surgery. These were immunostained using antibodies
gainst -SMA, vimentin, and desmin to determine the
ellular phenotypes of the adjacent tissue outside the graft
all. These markers were used to identify the presence of
yofibroblasts, fibroblasts, and contractile smooth muscle
ells (Table I).16 To confirm whether the implanted pacli-
axel inner-coated ePTFE graft affected the local tissue, we
ompared the cellular phenotypes of the surrounding tissue
utside the graft wall between the control and paclitaxel
nner-coated groups. In the control group, spindle-shaped
ells appeared to be SMA-positive, vimentin-positive, and
esmin-negative, suggesting that they were myofibro-
lasts.17-20 In the low-dose paclitaxel inner-coated
roup, many myofibroblasts were also frequently seen at
tomosis from (A and B) control grafts and from (C and
d grafts (Masson’s trichrome stain). Neointima can be
enous region of the cross-section.
and the (B) neointimal area between the control (n 6)
dose, n6). *Mean value of each group. All differences
statistically significant (P  .05 with unpaired Studentanas
coateosis
high
werehe boundaries between the graft and the adjacent tissue,
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March 2012812 Baek et aland a number of fibroblasts were found that were-SMA–
negative, vimentin-positive, and desmin-negative. There
were a few desmin-positive cells, meaning that fewer
contractile smooth muscle cells were present around the
implanted ePTFE graft. The cellular distributions of the
high-dose paclitaxel inner-coated group also showed
a similar appearance with the control and low-dose
groups.
As shown in Fig 8, the semiquantitative scores indi-
cated that the paclitaxel inner-coated graft did not suppress
the cellular proliferation, as did the noncoated control
graft.
DISCUSSION
Paclitaxel, an antiproliferative agent that acts by stabi-
lizing microtubules, inhibits smooth muscle cell prolifera-
tion and migration and prevents the neointimal hyperplasia
Fig 7. The cellular phenotypes of surrounding tissue o
control and (D-F) low-dose paclitaxel inner-coated graf
muscle actin (-SMA), (B and E) vimentin, and (C and
which were SMA-positive, vimentin-positive, and desmi
negative, vimentin-positive, and desmin-negative. Arro
SMA-negative, vimentin-negative, and desmin-positive (
Table 1. Determining the cellular phenotypes through
immunohistochemistry
Variable -SMA Vimentin Desmin
Smooth muscle cells  
 
Myofibroblasts   

Fibroblasts 
  

SMA, Smooth muscle actin.of hemodialysis grafts.21,22 This might explain the reduced bumber of myofibroblasts within the wall of paclitaxel-
reated grafts.5 The ability of myofibroblasts to produce a
ontractile force is essential for tissue contracture.23 During
he wound healing process, myofibroblasts are known to
nter the graft wall and pull adjacent structures together.24
When grafts coated with paclitaxel by the dipping
ethod were placed subcutaneously in rabbits, myofibro-
e the graft are shown in sequential sections of (A-C)
munohistochemically stained for (A and D) -smooth
smin. Arrow a indicates spindle-shaped myofibroblasts,
ative. Arrow b indicates fibroblasts, which were SMA-
indicates contractile smooth muscle cells, which were
al magnification, 400).
ig 8. Semiquantitative scores of cellular phenotypes in sur-
ounding tissue outside the graft wall, the site of which is indicated
n Fig 1, B. SMA, Smooth muscle actin. The error bars show the
tandard error.utsid
ts, im
F) de
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Volume 55, Number 3 Baek et al 813surrounding tissues.25 This could result in weaker adhesion
between the grafts and the surrounding tissue. Paclitaxel on
the outer surface of ePTFE grafts might prevent myofibro-
blast proliferation. There is a concern that these types of
coated grafts might cause hematomas, seromas, infections,
or pseudoaneurysms in the space between the graft and
surrounding tissue, thus resulting in incomplete hemodial-
ysis needle insertion.26 Therefore, we aimed to develop a
new coating method to deliver the drug mainly to the
luminal surface of ePTFE grafts to avoid such unwanted
effects while preserving the inhibiting effect of paclitaxel on
neointimal hyperplasia.
We investigated the cellular phenotypes at the adjacent
tissue outside the implanted grafts to determine whether
the paclitaxel inner-coated graft can influence myofibro-
blast proliferation. As a result, each group showed no
significant differences in the cellular distribution, which
suggested that paclitaxel inner-coated graft could effec-
tively suppress the neointimal formation and did not cause
any toxic reactions to the surrounding tissue.
There was no apparent dose effect between the low-
dose (0.22 g/mm2) and high-dose (0.69 g/mm2) pac-
litaxel inner-coated groups in preventing stenosis. Previ-
ously, several animal experiments using paclitaxel-coated
grafts made by the dipping method were conducted to
identify the effect of the drug-coating amount on the
inhibition of neointimal hyperplasia. In the case of the
dipped graft, the myofibroblast proliferation in the sur-
rounding tissue usually reduced significantly with increas-
ing concentration of paclitaxel coating. The low dose of
paclitaxel by the dip-coating method (0.13 g/mm2)
showed the similar cellular distribution with the noncoated
control group, but these grafts were often occluded by
stenosis. In contrast, even the high-dose (0.69 g/mm2)
of paclitaxel coating only on the luminal surface of graft
showed effective inhibition of the neointimal hyperplasia,
with little adverse tissue response.
Therefore, this inner-coating method can reduce the
coated amount of potentially toxic drug while preserving its
efficacy in inhibiting graft stenosis. If we were to implant 30
cm of a low-dose paclitaxel inner-coated graft (0.22 g/
mm2), about 1.2 mg of the paclitaxel would be exposed to
the patient. This amount is 1% of the commonly used
dose in chemotherapy. Moreover, because the drug would
be slowly released from the coated graft to the systemic
circulation over several weeks, there should be no systemic
toxic effects.
A clinical trial using a paclitaxel-eluting vascular wrap
was recently terminated prematurely because of the inci-
dence of graft infections. Paclitaxel release to the tissues
surrounding the graft carrying the drug over prolonged
periods could suppress the recipient’s immune response
and lead to infection, a common cause of graft loss.27
Accordingly, drug coating only on the luminal surface of
the graft at a level sufficient to prevent neointimal hyper-
plasia within the graft lumen and vessel—but not on the
outer surface—could have significant advantages.Arteriovenous grafts have many advantages. Compared
ith arteriovenous fistulas, vascular grafts require a short
aturation period, provide larger surface areas for cannu-
ation, and can be produced in various shapes and sizes for
mplantation.28-30 However, the critical problem of hemo-
ialysis grafts is the frequency of stenoses and thromboses,
articularly at the graft–venous anastomosis site, caused by
eointimal hyperplasia that results in significantly lower
atency. Therefore, ePTFE grafts coated with paclitaxel
nly on the luminal surface could overcome this critical
eakness.
ONCLUSIONS
Wehave developed a newmethod of applying paclitaxel
oating on the luminal surface of ePTFE grafts, with little
rug loading on the outer surface. With small amounts of
oated drug, such paclitaxel inner-coated ePTFE grafts
ould effectively suppress neointimal hyperplasia with little
nhibition of myofibroblast infiltration within the graft wall
nd surrounding tissues.
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